Last reviewed · How we verify
Atimos®
Atimos is a tiotropium bromide inhalation powder that acts as a long-acting anticholinergic (muscarinic antagonist) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.
Atimos is a tiotropium bromide inhalation powder that acts as a long-acting anticholinergic (muscarinic antagonist) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Atimos® |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | M3 muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Tiotropium blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. This produces sustained bronchodilation and improves lung function. The once-daily inhalation formulation provides 24-hour coverage for maintenance therapy in COPD.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Dry mouth
- Tremor
- Headache
- Pharyngitis
- Urinary retention
Key clinical trials
- Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients (PHASE2)
- A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD (PHASE3)
- Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients (PHASE4)
- Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atimos® CI brief — competitive landscape report
- Atimos® updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI